ACTIMMUNE (interferon gamma-1b) by Amgen is interferon-stimulated genes. First approved in 1999.
Drug data last refreshed 31m ago · AI intelligence enriched 1mo ago
ACTIMMUNE (interferon gamma-1b) is a recombinant Type 2 interferon that enhances macrophage oxidative metabolism, antibody-dependent cellular cytotoxicity, and natural killer cell activation. It is approved for chronic granulomatous disease (CGD) and severe malignant osteopetrosis (SMO), rare inherited immunodeficiency and bone disorders. The exact mechanism of efficacy in these conditions remains incompletely understood, as superoxide production changes do not predict treatment response.
As a mature biologic with LOE approaching, the ACTIMMUNE brand is likely transitioning from growth to legacy management with lean commercial teams focused on retention and efficiency.
interferon-stimulated genes. The three major groups of interferons (alpha, beta, gamma) have partially overlapping biological activities that include immunoregulation such as increased resistance to microbial pathogens and inhibition of cell proliferation. Type 1 interferons (alpha and beta) bind…
Interferon gamma
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on ACTIMMUNE at Amgen? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia
ACTIMMUNE in Intermediate Osteopetrosis
Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study
Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on ACTIMMUNE offers stability in a niche orphan disease franchise with deep customer relationships and predictable patient populations, but limited growth potential and shrinking team sizes as LOE approaches. Roles focus on retention, compliance, and efficient management rather than market expansion or innovation.